GLPG 1205

Drug Profile

GLPG 1205

Alternative Names: GLPG-1205

Latest Information Update: 06 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Galapagos NV
  • Class Anti-inflammatories; Antifibrotics
  • Mechanism of Action GPR84 protein antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Idiopathic pulmonary fibrosis
  • Phase I Inflammatory bowel diseases
  • Discontinued Ulcerative colitis

Most Recent Events

  • 18 Jun 2018 Phase-II clinical trials in Idiopathic pulmonary fibrosis in Slovakia (PO) (EudraCT2017-004302-18)
  • 22 Feb 2018 Galapagos plans a phase II trial in Idiopathic pulmonary fibrosis in 2018
  • 31 Dec 2017 Galapagos NV has US and European patents, and pending applications in USA, Europe, Australia, Canada and other countries, related to GLPG 1205
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top